New research reveals that patients who stop using new slimming jabs like semaglutide or tirzepatide may regain shed pounds far faster than those who end conventional diet and exercise plans.
Findings released in a major health publication points out that while obese people can lose a large proportion of their total mass while undergoing treatment, the weight returns at an estimated rate of nearly a kilo each month after stopping.
"Individuals buying these treatments should be aware of the risk of quick weight regain when the therapy is stopped," warns expert Dr. Susan Jebb.
This pace of regain suggests a return to starting mass in about 18 months.
Comparing Therapies
The study, which examined 37 of studies involving over 9,000 of participants, compared the effects of the injectable medications with other pills.
Scientists point out that people who shed pounds through diet and exercise typically experience a slower weight regain—around 100 grams monthly—post-intervention.
Explaining the Quick Rebound
Nutrition scientists believe the way of the jabs explains the amplified weight return.
These medications mimic a body's own chemical called GLP-1, which helps regulate appetite.
"Artificially providing GLP-1 concentrations far above than normal might result in the system to generate a reduced amount of its own natural GLP-1, and could lessen responsiveness to its effects," explained Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this hormone supplement means hunger is unsuppressed, making excessive eating far more likely."
A Chronic Disease?
Health authorities recommend the jabs for people with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications.
A number of clinicians argue that, due to the significant potential of weight regain, the therapy should be considered life-long.
This perspective is supported by drug manufacturers, who say that the results "underscore the persistent character of obesity," similar to managing conditions like hypertension.
User Testimonies
Individuals who have come off the medication describe a intense return of cravings.
"I experienced a trigger flipping and I was suddenly ravenous," recalled an individual.
This difficulty is worsened if individuals have not established sustainable dietary or behavioural changes during therapy.
Widespread Use
Survey data suggest that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with demand continuing to grow.
- Use is more common among women than men.
- The 40s and 50s age group shows the greatest level of interest.
- A large proportion obtain the medications through private prescriptions rather than public health services.
Finally, researchers stress that while these medications are powerful agents for shedding pounds, they are not a magic fix and maintained weight loss relies on ongoing lifestyle management.
